Vision of Huawei Industrial Fund
The Future of Huawei Industrial Fund
The Future of Huawei Industrial Fund
Our goal is to accelerate the delivery of key medicines and technologies to market by providing investment, clinical trials, regulatory filing, and commercialization support for late-stage pipelines—not only as investors, but also as active participants.
We partner with pharmaceutical, biotech, and medtech companies to address unmet medical needs and improve quality of life for patients in China and worldwide.
Commercialized products to date
Investment MDs
Peak annual sales per product (RMB 100M)
Commercialization team members
Investment strategy
Over the next 20 years, China's share of global population is expected to decline from 17% to 13.7%, while its GDP share may rise from 17.8% to 27%, making it likely to become the world's largest economy. Healthcare affordability in China is strengthening, yet rapid aging (with the 65+ population projected to reach or exceed 25%) will create hard budget constraints focused on full-cycle value for money while maintaining efficacy. With China's rising international standing and advantages in clinical data and biomanufacturing scale, healthcare models with Chinese characteristics will evolve toward international and digital innovation, producing medicines that serve both domestic and global markets. Our BD incubation fund continues to support companies in this space.
● Filling the gap: BD M&A funds bridge the gap between pipeline R&D and commercialization—management accountability and financing windows that are often missing. Life sciences is experiencing unprecedented innovation driven by rapid advances in science and technology, yet funding to translate breakthroughs into products remains insufficient. Our BD M&A fund partners with leading pharma, biotech, and medtech companies as both investors and participants to advance critical-path products and deliver them to patients sooner.
● Deep expertise and resources: The fund combines strong investment and capital access with DIA and Beijing Huawei Health Group's global regulatory resources, clinical, commercial, and operational expertise. We commit our capabilities and scale through hands-on participation to identify, fund, and advance the most promising life-science products and companies.
● Lower risk, quality markets, uncorrelated returns: We pursue flexible strategies that reduce risk while delivering attractive value—for example, supporting late-stage development of innovative core products with not only capital but also the regulatory and commercialization commitments partners often lack. Our goal is to capture value directly from funded products and achieve stable, absolute returns uncorrelated with public markets.
We operate a four-tier decision process: BD initiation → expert advisory committee consultation → investment team evaluation → investment committee vote. BD tracks execution and flags risks; the advisory committee guides policy and industry risk; the investment team submits investment and risk proposals; the committee decides by one-person-one-vote to ensure rigor and compliance.
Our investment philosophy prioritizes exit. Across the fund lifecycle, we use portfolio company budgets and risks as coordinates—a full-cycle comprehensive budget management system—to actively manage seven core risks and deliver expected returns.
Establish post-investment tracking for underlying asset rights that cap fund returns, and help optimize license-in, co-development, and co-commercialization terms (territory, indications, milestones, supply/tech transfer, IP ownership, default and buyback).
For registration and clinical work affecting operating efficiency: assist and monitor clinical cooperation with tertiary/specialty alliances, and accelerate bridging trials, real-world studies, and ethics/enrollment.
For manufacturing and quality risks affecting investment intensity: assist and monitor CDMO/CMO frameworks, GMP setup, scale-up, validation batches, consistency evaluation, and locking key materials and capacity.
For commercialization risks: assist and monitor pilot hospital access, department partnerships, medical promotion, KOL systems, patient management, and flagship center milestones.
For collection risks: conduct pharmacoeconomics jointly, develop insurance/commercial payer plans, drive provincial access and volume-based procurement contingency, and implement payment and access.
For valuation growth: facilitate co-development and product iteration; for devices, drive indication expansion, software upgrades, and consumable bundling for recurring revenue.
For exit risks: help structure milestone payments, staged investments, earn-outs, exit auctions, and liquidation compensation mechanisms.
Address: 28th Floor, Nanyin Building, No. 2 East Third Ring North Road, Chaoyang District, Beijing
Phone: 010-61006202
Personnel recruitment consultation: li-ll@moh-hw.com
Investment and BD cooperation: BD@moh-hw.com
Medical sales consultation: zhang-b@moh-hw.com
Huawei Health Management Group. All Rights Reserved (C) 2021
Powered by PharmNet.com.cn Toocle NetSun Copyright Notice 京ICP备2026038759
Online Drug and Medical Device Information Service Filing: Non-commercial -(京) Online Drug and Device Information Record No. (2026) 00146